The US FDA seems prepared for the return of Zelnorm (tegaserod maleate), a treatment for irritable bowel syndrome with constipation (IBS-C), to the American market, although the agency is seeking advisory committee input on the most appropriate subpopulation for which the benefits outweigh the risks.
The Gastrointestinal Drugs Advisory Committee will convene Oct. 17 primarily to assess the 5-HT4 receptor agonist's cardiovascular (CV) risks and...





